Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Radioresistance of Non-Small Cell Lung Cancers and Therapeutic Perspectives.
Césaire M, Montanari J, Curcio H, Lerouge D, Gervais R, Demontrond P, Balosso J, Chevalier F. Césaire M, et al. Among authors: curcio h. Cancers (Basel). 2022 Jun 8;14(12):2829. doi: 10.3390/cancers14122829. Cancers (Basel). 2022. PMID: 35740495 Free PMC article. Review.
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Campelo RG, Madroszyk A, Mazières J, Curcio H, Wasąg B, Pretzenbacher Y, Grillet F, Dingemans AC, Dziadziuszko R. Remon J, et al. Among authors: curcio h. J Clin Oncol. 2024 Apr 20;42(12):1350-1356. doi: 10.1200/JCO.23.01521. Epub 2024 Feb 7. J Clin Oncol. 2024. PMID: 38324744
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma.
Tagliamento M, Bironzo P, Curcio H, De Luca E, Pignataro D, Rapetti SG, Audisio M, Bertaglia V, Paratore C, Bungaro M, Olmetto E, Artusio E, Reale ML, Zichi C, Capelletto E, Carnio S, Buffoni L, Passiglia F, Novello S, Scagliotti GV, Di Maio M. Tagliamento M, et al. Among authors: curcio h. Crit Rev Oncol Hematol. 2022 Apr;172:103639. doi: 10.1016/j.critrevonc.2022.103639. Epub 2022 Feb 19. Crit Rev Oncol Hematol. 2022. PMID: 35192932 Free article. Review.
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).
Vergnenegre A, Monnet I, Ricordel C, Bizieux A, Curcio H, Bernardi M, Corre R, Guisier F, Hominal S, Le Garff G, Bylicki O, Locher C, Geier M, Chouaïd C, Robinet G; GFPC team. Vergnenegre A, et al. Among authors: curcio h. Lung Cancer. 2023 Apr;178:191-197. doi: 10.1016/j.lungcan.2023.02.020. Epub 2023 Feb 27. Lung Cancer. 2023. PMID: 36868180 Clinical Trial.
Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study.
Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, Gross-Goupil M, Ladoire S, Borchiellini D, Geoffrois L, Joly F, Priou F, Barthelemy P, Laramas M, Narciso B, Thiery-Vuillemin A, Berdah JF, Ferrari V, Dominique Thomas Q, Mione C, Curcio H, Oudard S, Tantot F, Escudier B, Chabaud S, Albiges L, Thibault C. Velev M, et al. Among authors: curcio h. Eur J Cancer. 2023 Mar;182:66-76. doi: 10.1016/j.ejca.2022.12.028. Epub 2023 Jan 13. Eur J Cancer. 2023. PMID: 36746010 Clinical Trial.
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer.
Doubre H, Greillier L, Justeau G, Ricordel C, Swalduz A, Curcio H, Bylicki O, Auliac JB, Guisier F, Bigay-Game L, Bernardi M, Pinsolle J, Amrane K, Decroisette C, Descourt R, Chouaid C, Geier M. Doubre H, et al. Among authors: curcio h. J Cancer Res Clin Oncol. 2023 Nov;149(16):15095-15102. doi: 10.1007/s00432-023-05321-w. Epub 2023 Aug 25. J Cancer Res Clin Oncol. 2023. PMID: 37626173
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
Decroisette C, Greillier L, Curcio H, Pérol M, Ricordel C, Auliac JB, Falchero L, Veillon R, Vieillot S, Guisier F, Marcq M, Justeau G, Bigay-Game L, Bernardi M, Doubre H, Pinsolle J, Amrane K, Chouaïd C, Descourt R. Decroisette C, et al. Among authors: curcio h. J Immunother. 2023 Oct 9. doi: 10.1097/CJI.0000000000000490. Online ahead of print. J Immunother. 2023. PMID: 37807621
Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).
Auliac JB, Thomas PA, Bylicki O, Guisier F, Curcio H, AlainVegnenègre, Swalduz A, Wislez M, Le Treut J, Decroisette C, Basse V, Falchero L, De Chabot G, Moreau D, Huchot E, Lupo Mansuet A, Blons H, Chouaïd C, Greillier L. Auliac JB, et al. Among authors: curcio h. Ther Adv Med Oncol. 2024 Mar 6;16:17588359241236451. doi: 10.1177/17588359241236451. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38455711 Free PMC article.
Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort.
Nannini S, Guisier F, Curcio H, Ricordel C, Demontrond P, Abdallahoui S, Baloglu S, Greillier L, Chouaid C, Schott R. Nannini S, et al. Among authors: curcio h. Curr Oncol. 2024 Mar 21;31(3):1656-1666. doi: 10.3390/curroncol31030126. Curr Oncol. 2024. PMID: 38534959 Free PMC article.